The discovery and development of potent anti-hepatitis C virus (HCV) therapies has been a hotly contested field for global pharmaceutical companies over the last few decades. Some natural products, such as sangliferin A (SfA), have demonstrated potent anti-HCV activity through the inhibition of a clinically validated target, cyclophilin A (CypA).
Unfortunately, the chemical complexity of SfA and poor oral bioavailability have derailed all early drug development attempts.
This case study:
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK
Email: privacy@technologynetworks.com
© 2019 Technology Networks. All rights reserved
Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy